Clinical Significance of a Prospective Large Genomic Screening for SCLC: The Genetic Classification and a Biomarker-Driven Phase 2 Trial of Gedatolisib

Authors: Umemura, Shigeki ^a, Udagawa, Hibiki ^a, Ikeda, Takaya ^a, Murakami, Haruyasu ^b, Daga, Haruko ^c, Toyozawa, Ryo ^d, Kozuki, Toshiyuki ^e, Sakakibara-Konishi, Jun ^f, Ohe, Yuichiro ^g, Morise, Masahiro ^h, Kato, Terufumi ⁱ, Shingyoji, Masato ^j, Hara, Satoshi ^k, Furuya, Naoki ^l, Teranishi, Shuhei ^m, Takata, Saori ⁿ, Miyamoto, Shingo ^o, Nakachi, Ichiro ^p, Wakabayashi, Masashi ^q, Nomura, Shogo ^{q, r}, Sato, Akihiro ^q, Ishii, Genichiro ^s, Tsuchihara, Katsuya ^t, Sugiyama, Eri ^a, Kirita, Keisuke ^a, Sakai, Tetsuya ^a, Shibata, Yuji ^a, Izumi, Hiroki ^a, Nosaki, Kaname ^a, Zenke, Yoshitaka ^a, Matsumoto, Shingo ^a, Yoh, Kiyotaka ^a, Niho, Seiji ^a, Goto, Koichi ^{a, ∗}

Source: In Journal of Thoracic Oncology February 2025 20(2):177-193

A Single-Arm Phase 2 Study of Sotorasib Plus Carboplatin/Pemetrexed in Patients With Advanced Nonsquamous NSCLC With KRAS G12C Mutation (WJOG14821L, SCARLET)

Authors: Akamatsu, Hiroaki ^{a, ∗}, Sakata, Shinya ^b, Azuma, Koichi ^c, Yoshioka, Hiroshige ^d, Uemura, Takehiro ^e, Tsuchiya-Kawano, Yuko ^f, Esumi, Seiya ^g, Kurosaki, Takashi ^h, Sato, Yuki ⁱ, Sakamoto, Tomohiro ^j, Ninomiya, Kiichiro ^k, Toyozawa, Ryo ^l, Yoneshima, Yasuto ^m, Shukuya, Takehito ⁿ, Kozuki, Toshiyuki ^o, Watanabe, Kana ^p, Daga, Haruko ^q, Kato, Terufumi ^r, Takahashi, Toshiaki ^s, Osuga, Mitsuo ^t, Koh, Yasuhiro ^{a, t}, Morita, Satoshi ^u, Yamamoto, Nobuyuki ^a

Source: In Journal of Thoracic Oncology January 2025

Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study

Authors: Kenmotsu, Hirotsugu, Sakai, Kazuko, Mori, Keita, Kato, Terufumi, Sugawara, Shunichi, Kirita, Keisuke, Yoneshima, Yasuto, Azuma, Koichi, Nishino, Kazumi, Teraoka, Shunsuke, Koyama, Ryo, Masuda, Ken, Hayashi, Hidetoshi, Toyozawa, Ryo, Miura, Satoru, Sato, Yuki, Nakagawa, Kazuhiko, Yamamoto, Nobuyuki, Nishio, Kazuto, Takahashi, Toshiaki

Source: In JTO Clinical and Research Reports November 2024 5(11)

Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia

Authors: Kato, Yuki, Udagawa, Hibiki, Matsumoto, Shingo, Izumi, Hiroki, Ohe, Yuichiro, Kato, Terufumi, Nishino, Kazumi, Miyamoto, Shingo, Kawana, Sachiko, Chikamori, Kenichi, Shingyoji, Masato, Sato, Yuki, Takada, Yuji, Toyozawa, Ryo, Azuma, Koichi, Tanaka, Yu, Sakai, Tetsuya, Shibata, Yuji, Sugiyama, Eri, Nosaki, Kaname, Zenke, Yoshitaka, Umemura, Shigeki, Yoh, Kiyotaka, Seike, Masahiro, Goto, Koichi

Source: In Lung Cancer November 2024 197

Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia

Authors: Okahisa, Masanobu, Udagawa, Hibiki, Matsumoto, Shingo, Kato, Terufumi, Yokouchi, Hiroshi, Furuya, Naoki, Kanemaru, Ryota, Toyozawa, Ryo, Nishiyama, Akihiro, Ohashi, Kadoaki, Miyamoto, Shingo, Nishino, Kazumi, Nakamura, Atsushi, Iwama, Eiji, Niho, Seiji, Oi, Hajime, Sakai, Tetsuya, Shibata, Yuji, Izumi, Hiroki, Sugiyama, Eri, Nosaki, Kaname, Umemura, Shigeki, Zenke, Yoshitaka, Yoh, Kiyotaka, Kah Mun Low, Grace, Zhuo, Jianmin, Goto, Koichi

Source: In Lung Cancer May 2024 191

Brigatinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer: Final results of the phase 2 J‐ALTA trial

Authors: Yoshida, Tatsuya, Kumagai, Toru, Toyozawa, Ryo, Katayama, Ryohei, Nishio, Makoto, Seto, Takashi, Goto, Koichi, Yamamoto, Nobuyuki, Ohe, Yuichiro, Kudou, Kentarou, Asato, Takayuki, Zhang, Pingkuan, Nakagawa, Kazuhiko

Source: Cancer science. 114(9):3698-3707

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100191751128.0x000001&indx=1&recIds=ETOCvdc_100191751128.0x000001

Phase 1 study of DS‐1205c combined with gefitinib for EGFR mutation‐positive non‐small cell lung cancer

Authors: Goto, Koichi, Shiraishi, Yoshimasa, Murakami, Haruyasu, Horinouchi, Hidehito, Toyozawa, Ryo, Takeda, Masayuki, Uno, Makiko, Crawford, Nigel, McGill, Joseph, Jimbo, Takeshi, Ishigami, Masato, Takayama, Gensuke, Nakayama, Shintaro, Ohwada, Shoichi, Nishio, Makoto

Source: Cancer medicine. 12(6):7090-7104

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185281332.0x000001&indx=1&recIds=ETOCvdc_100185281332.0x000001

Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L)

Authors: Tachihara, Motoko, Hata, Akito, Tokito, Takaaki, Hara, Satoshi, Okada, Hideaki, Miura, Satoru, Sato, Yuki, Tabata, Eriko, Watanabe, Hiroshi, Takayama, Yusuke, Toyozawa, Ryo, Ota, Keiichi, Wakuda, Kazushige, Nakamura, Atsushi, Shimokawa, Mototsugu, Yamamoto, Nobuyuki, Nakagawa, Kazuhiko

Source: In JTO Clinical and Research Reports October 2023 4(10)

Nazartinib for treatment-naive EGFR-mutant non−small cell lung cancer: Results of a phase 2, single-arm, open-label study

Authors: Tan, Daniel S.W., Kim, Sang-We, Ponce Aix, Santiago, Sequist, Lecia V., Smit, Egbert F., Yang, James C.H., Hida, Toyoaki, Toyozawa, Ryo, Felip, Enriqueta, Wolf, Juergen, Grohé, Christian, Leighl, Natasha B., Riely, Gregory, Cui, Xiaoming, Zou, Mike, Ghebremariam, Samson, O'Sullivan-Djentuh, Leslie, Belli, Riccardo, Giovannini, Monica, Kim, Dong-Wan

Source: European journal of cancer. 172:276-286

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100170792083.0x000001&indx=1&recIds=ETOCvdc_100170792083.0x000001

Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study

Authors: Kenmotsu, Hirotsugu, Wakuda, Kazushige, Mori, Keita, Kato, Terufumi, Sugawara, Shunichi, Kirita, Keisuke, Yoneshima, Yasuto, Azuma, Koichi, Nishino, Kazumi, Teraoka, Shunsuke, Shukuya, Takehito, Masuda, Ken, Hayashi, Hidetoshi, Toyozawa, Ryo, Miura, Satoru, Fujimoto, Daichi, Nakagawa, Kazuhiko, Yamamoto, Nobuyuki, Takahashi, Toshiaki

Source: In Journal of Thoracic Oncology September 2022 17(9):1098-1108

Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial

Authors: Nishio, Makoto, Yoshida, Tatsuya, Kumagai, Toru, Hida, Toyoaki, Toyozawa, Ryo, Shimokawaji, Tadasuke, Goto, Koichi, Nakagawa, Kazuhiko, Ohe, Yuichiro, Seto, Takashi, Kudou, Kentarou, Asato, Takayuki, Zhang, Pingkuan, Yamamoto, Nobuyuki

Source: In Journal of Thoracic Oncology March 2021 16(3):452-463

Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors

Authors: Takamori, Shinkichi ^*, Takada, Kazuki, Shimokawa, Mototsugu, Matsubara, Taichi, Fujishita, Takatoshi, Ito, Kensaku, Toyozawa, Ryo, Yamaguchi, Masafumi, Okamoto, Tatsuro, Yoneshima, Yasuto, Tanaka, Kentaro, Okamoto, Isamu, Tagawa, Tetsuzo, Mori, Masaki

Source: In Lung Cancer February 2021 152:27-33

Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer

Authors: Calvo, Emiliano, Spira, Alexander, Miguel, María de, Kondo, Shunsuke, Gazzah, Anas, Millward, Michael, Prenen, Hans, Rottey, Sylvie, Warburton, Lydia, Alanko, Tuomo, Cassier, Philippe A., Yoh, Kiyotaka, Italiano, Antoine, Moreno, Victor, Peltola, Katriina, Seto, Takashi, Toyozawa, Ryo, Afar, Daniel E., Englert, Stefan, Komarnitsky, Philip, Lambert, Stacie, Parikh, Apurvasena, Vosganian, Gregory, Gao, Bo

Source: In Cancer Treatment and Research Communications 2021 28

Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy

Authors: Matsubara, Taichi, Takamori, Shinkichi, Fujishita, Takatoshi, Toyozawa, Ryo, Ito, Kensaku, Yamaguchi, Masafumi, Seto, Takashi, Okamoto, Tatsuro

Source: Thoracic cancer. 12(23):3286-3289

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100135824150.0x000001&indx=1&recIds=ETOCvdc_100135824150.0x000001

Sarcoid‐like reaction of the extrathoracic lymph node in a patient with lung adenocarcinoma treated with pembrolizumab

Authors: Takamori, Shinkichi, Furubayashi, Nobuki, Taguchi, Kenichi, Matsubara, Taichi, Fujishita, Takatoshi, Ito, Kensaku, Yamaguchi, Masafumi, Toyozawa, Ryo, Seto, Takashi, Negishi, Takahito, Nakamura, Motonobu, Okamoto, Tatsuro

Source: Thoracic cancer. 12(14):2122-2125

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100123683951.0x000001&indx=1&recIds=ETOCvdc_100123683951.0x000001

The Influence of Clinical T Factor on Predicting Pathologic N Factor in Resected Lung Cancer

Authors: Shimamatsu, Shinichiro, Takenoyama, Mitsuhiro, Shimokawa, Mototsugu, Takada, Kazuki, Edagawa, Makoto, Toyozawa, Ryo, Nosaki, Kaname, Oba, Taro, Tagawa, Tetsuzo, Yamaguchi, Masafumi, Taguchi, Kenichi, Seto, Takashi

Source: In The Annals of Thoracic Surgery October 2019 108(4):1080-1086

Cohesion between pulmonary artery and bronchus after immune checkpoint inhibitor therapy in a lung cancer patient

Authors: Takamori, Shinkichi, Takenoyama, Mitsuhiro, Matsubara, Taichi, Fujishita, Takatoshi, Ito, Kensaku, Yamaguchi, Masafumi, Toyozawa, Ryo, Seto, Takashi, Okamoto, Tatsuro

Source: Thoracic cancer. 11(12):3605-3608

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100111929496.0x000001&indx=1&recIds=ETOCvdc_100111929496.0x000001

A randomized phase 3 study of maintenance therapy with S‐1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus S‐1 for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L)

Authors: Tanaka, Kaoru, Morita, Satoshi, Ando, Masahiko, Yokoyama, Takuma, Nakamura, Atsushi, Yoshioka, Hiroshige, Ishiguro, Takashi, Miura, Satoru, Toyozawa, Ryo, Oguri, Tetsuya, Daga, Haruko, Ko, Ryo, Bessho, Akihiro, Tachihara, Motoko, Iwamoto, Yasuo, Hirano, Katsuya, Nakanishi, Yoichi, Nakagawa, Kazuhiko, Yamamoto, Nobuyuki, Okamoto, Isamu

Source: Cancer. 126(16):3648-3656

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100111777006.0x000001&indx=1&recIds=ETOCvdc_100111777006.0x000001

Predictive and prognostic impact of primary tumor‐bearing lobe in nonsmall cell lung cancer patients treated with anti‐PD‐1 therapy

Authors: Takamori, Shinkichi, Takada, Kazuki, Shimokawa, Mototsugu, Matsubara, Taichi, Haratake, Naoki, Miura, Naoko, Toyozawa, Ryo, Yamaguchi, Masafumi, Takenoyama, Mitsuhiro, Yoneshima, Yasuto, Tanaka, Kentaro, Okamoto, Isamu, Tagawa, Tetsuzo, Mori, Masaki

Source: International journal of cancer. 147(8):2327-2334

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100108083731.0x000001&indx=1&recIds=ETOCvdc_100108083731.0x000001

Longitudinal monitoring of somatic genetic alterations in circulating cell‐free DNA during treatment with epidermal growth factor receptor–tyrosine kinase inhibitors

Authors: Iwama, Eiji, Sakai, Kazuko, Hidaka, Noriko, Inoue, Koji, Fujii, Akiko, Nakagaki, Noriaki, Ota, Keiichi, Toyozawa, Ryo, Azuma, Koichi, Nakatomi, Keita, Harada, Taishi, Hisasue, Junko, Sakata, Shinya, Shimose, Takayuki, Kishimoto, Junji, Nakanishi, Yoichi, Nishio, Kazuto, Okamoto, Isamu

Source: Cancer. 126(1):219-227

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100094298410.0x000001&indx=1&recIds=ETOCvdc_100094298410.0x000001